Please assess the completion status of the following clinical trial:

Trial Title: Phase 1 Placebo-controlled, Randomized Trial of an Adenoviral-vector Based Norovirus Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female volunteers aged 18 - 49 years, inclusive~2. Able to give written informed consent~3. Healthy (no clinically significant health concerns)~4. Safety laboratory values within the following range criteria normal range~5. Body mass index between 17 and 35 at screening~Exclusion Criteria:~1. Receipt of any investigational norovirus vaccine within two years prior to study~2. Receipt of any investigational vaccine, drug or device within 8 weeks preceding vaccination~3. Administration of any licensed vaccine within 30 days prior to study~4. Presence of significant uncontrolled medical or psychiatric illness (acute or chronic) including institution of new medical/surgical treatment or significant dose alteration for uncontrolled symptoms or drug toxicity within 3 months of screening and reconfirmed at baseline~5. History of drug, alcohol or chemical abuse within 1 year prior to vaccination~6. Presence of a fever ≥ 38oC measured orally at baseline~7. Stool sample with occult blood at screening -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- H1N1 (high dose) Oral Vaccine Tablet (Type: EXPERIMENTAL): Singe dose of orally administered VXA-G1.1-NN (high dose) Oral Vaccine Tablet. VXA-G1.1-NN is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of noroviral gastroenteritis caused by Norovirus GI.1. The vaccine vector encodes for a full length VP1 (major capsid protein) gene from Norvirus GI.1 Norwalk.
- H1N1 (low dose) Oral Vaccine Tablet (Type: EXPERIMENTAL): Singe dose of orally administered VXA-G1.1-NN (low dose) Oral Vaccine Tablet. VXA-G1.1-NN is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of noroviral gastroenteritis caused by Norovirus GI.1. The vaccine vector encodes for a full length VP1 (major capsid protein) gene from Norvirus GI.1 Norwalk.
- Placebo Tablets (Type: PLACEBO_COMPARATOR): Singe dose of VXA Placebo tablets. The placebo tablets are small off-white tablets that are similar in size and number to the active vaccine dose being delivered.

Based on this trial design, predict the completion outcome and termination type (if applicable).